Treatment of resistance to Binimetinib

Binimetinib and encorafenib from Array BioPharma are part of an oral BRAF/MEK inhibitor combination therapy and both are oral small molecule kinase inhibitors. Approximately50% of patients diagnosed with metastatic melanoma test positive for BRAF mutations, the most common genetic mutation in metastatic melanoma. BRAF mutations are rare in non-small cell lung cancer, occurring in 2% to 5% of cases.

If a patient develops drug resistance during combined treatment with bimetinib and canafilib, he or she should promptly inform the doctor. Since everyone has a different constitution and has different drug resistance responses, the doctor may understand the patient's individual genetic variation and adjust the treatment plan according to his or her specific genetic background. This helps ensure more effective treatment and reduces the risk of drug resistance. Combination therapy with other drugs may alleviate resistance to bimetinib. For example, combined use with crizotinib (Cobimetinib) or other signaling pathway inhibitors can exert a synergistic effect and enhance the therapeutic effect. Periodically interrupt bimetinib use to prevent the development of resistance. This treatment strategy reduces sustained exposure to the drug, thereby reducing the risk of drug resistance developing.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.